Anteroposterior Versus Anterolateral Electrode Position for Electrical Cardioversion of Atrial Fibrillation

Recruiting N/A Interventional Study
Atrial Fibrillation Atrial Flutter
No Placebo Group Every participant receives an active treatment — no one gets a placebo.
Ready to participate?

Review the details below, then apply to join this clinical trial.

At a Glance
Age
18 and older
Sex
Any
Study type
Interventional
Purpose
Treatment
Participants needed
1,750 (estimated)
Sponsor
McMaster University · Other
Think this trial could be right for you?

Answer a few quick questions to see if you may meet the eligibility requirements.

Check Your Eligibility
About This Trial
Atrial fibrillation is the most common heart rhythm disorder (arrhythmia) worldwide. Nearly 40 million people are affected by atrial fibrillation worldwide, and this number is expected to increase by over 50% by 2050. Atrial fibrillation can cause strokes, heart attacks, heart failure, poor quality of life and even death. Almost half a million deaths worldwide are expected to be related to atrial …
Trial Locations
Loading…

Loading trial locations…

Eligibility Criteria
Inclusion Criteria: Consenting adult patients scheduled for non-emergent electrical cardioversion of Atrial Fibrillation or Flutter Exclusion Criteria: 1. Insufficiently anticoagulation for cardioversion as per Canadian Cardiovascular Society guidelines or have not undergone trans-esophageal echo…
Contacts

William McIntyre, MD

9055212100

william.mcintyre@phri.ca

CONTACT